DNAH5 Gene Primary ciliary dyskinesia type 3 Genetic Test
Cost: AED 4400.0
Test Name: DNAH5 Gene Primary ciliary dyskinesia type 3 Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test type: Ear Nose Throat Disorders
Doctor: ENT Doctor
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS19
Test Details
The DNAH5 gene is associated with Primary Ciliary Dyskinesia (PCD) type 3, which is a rare genetic disorder characterized by abnormalities in the structure and function of cilia. Cilia are tiny hair-like structures found on the surface of cells that play a crucial role in moving mucus, bacteria, and other substances out of the respiratory tract, reproductive tract, and other organs.
A NGS (Next-Generation Sequencing) genetic test for DNAH5 gene mutations can help diagnose PCD type 3. NGS is a high-throughput DNA sequencing technology that can analyze multiple genes simultaneously, providing a comprehensive assessment of genetic variations in a single test. By analyzing the DNAH5 gene, this test can identify specific mutations or variations that may be responsible for causing PCD type 3.
This information can help confirm a diagnosis, guide treatment decisions, and provide important information for genetic counseling. It is important to note that genetic testing for PCD type 3 should be done by a qualified healthcare professional or genetic counselor who can interpret the results and provide appropriate guidance and support.
| Test Name | DNAH5 Gene Primary ciliary dyskinesia type 3 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Ear Nose Throat Disorders |
| Doctor | ENT Doctor |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with IARS2 Gene Cataracts, growth hormone deficiency, sensory neuropathy, sensorineural hearing loss, and skeletal dysplasia NGS Genetic DNA Test gene IARS19 |
| Test Details | The DNAH5 gene is associated with Primary Ciliary Dyskinesia (PCD) type 3, which is a rare genetic disorder characterized by abnormalities in the structure and function of cilia. Cilia are tiny hair-like structures found on the surface of cells that play a crucial role in moving mucus, bacteria, and other substances out of the respiratory tract, reproductive tract, and other organs. A NGS (Next-Generation Sequencing) genetic test for DNAH5 gene mutations can help diagnose PCD type 3. NGS is a high-throughput DNA sequencing technology that can analyze multiple genes simultaneously, providing a comprehensive assessment of genetic variations in a single test. By analyzing the DNAH5 gene, this test can identify specific mutations or variations that may be responsible for causing PCD type 3. This information can help confirm a diagnosis, guide treatment decisions, and provide important information for genetic counseling. It is important to note that genetic testing for PCD type 3 should be done by a qualified healthcare professional or genetic counselor who can interpret the results and provide appropriate guidance and support. |
